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This systematic review and meta-analysis aims to determine the efficacy and safety of 
droxidopa in the treatment of orthostatic hypotension (OH), following its recent approvals in 
the US. 
Methods 
MEDLINE, EMBASE, PubMed, Cochrane Controlled Trials Register, Web of Science, 
ProQuest and the WHO Clinical Trials Registry were searched.  Studies were included if they 
randomised adults with OH to droxidopa or to control, and outcomes related to symptoms, 
daily activity, blood pressure or adverse events. Data was extracted independently by two 
reviewers. Risk of bias was judged against the Cochrane risk of bias tool and quality of 
evidence measured using GRADE criteria. A fixed-effects model was used for pooled 
analysis. 
Results 
Of 224 identified records, four studies met eligibility, with a pooled sample size of 494. 
Study duration was between one and eight weeks. Droxidopa was effective at reducing 
dizziness [mean difference -0.97 (95% confidence interval -1.51, -0.42)], overall symptoms [-
0.52 (-0.98, -0.06)] and difficulty with activity [-0.86 (-1.34, -0.38)]. Droxidopa was also 
effective at improving standing systolic blood pressure [3.9 (0.1, 7.69)]. Rates of adverse 
events were similar between droxidopa and control groups, including supine hypertension 




Droxidopa is safe and effective at reducing the symptoms associated with neurogenic OH 
without increasing the risk of supine hypertension. 









Orthostatic hypotension (OH) is a disabling condition, resulting from a sustained reduction in 
blood pressure (BP, ≥20 mmHg systolic or ≥10 mmHg diastolic) within 3 minutes of standing 
[1]. It is highly prevalent in those with chronic disease; affecting approximately 17% of older 
people with hypertension, 25% of people with type 2 diabetes and up to 60% of people with 
Parkinson’s disease [2-5]. Evidence to support existing treatment options for OH is of poor 
quality, creating uncertainty in the management of the condition [6-9]. 
Droxidopa is an oral pharmacological agent which is metabolised both peripherally and 
centrally into norepinephrine by dopadecarboxylase. It has been used in Japan since 1989 to 
treat neurogenic OH, but it has not been approved for use in Europe or America [10]. That is 
until February 2014 when the United States’ Food and Drug Administration granted the use of 
droxidopa for the treatment of symptomatic OH secondary to primary autonomic failure, 
dopamine β-hydroxylase deficiency (DBHD) or non-diabetic autonomic neuropathy [11]. 
Early phase studies in the 1980s and 1990s looked promising, particularly in DBHD – a rare 
genetic disorder in which dopamine cannot be converted into norepinephrine [12-15]. 
However, the following decade produced larger efficacy studies demonstrating significant 
improvements in standing BP and orthostatic symptoms in individuals with autonomic 
neuroapthy [16-18]. In recent years, several large phase 3 clinical trials have been reported, but 
as yet no systematic review or synthesis of results has been performed. The results of such a 
review and analysis would be timely and informative both for clinicians and policy makers and 
are presented here. 
Methods 
Eligibility criteria 
To be eligible for inclusion all studies were required to meet the following criteria: 
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 Participants: Aged over 18 years, with OH according to international consensus 
criteria (systolic drop of at least 20 mm Hg or diastolic drop of at least 10 mm 
Hg within 3 minutes of standing) [1]. Studies relating to healthy participants, 
astronauts and OH secondary to acute illness (such as haemorrhage) or 
haemodialysis were excluded. 
 Intervention: This review considered the use of droxidopa, administered orally 
at any dose, when compared to placebo. 
 Outcomes: Studies were required to include at least one measure of symptoms, 
blood pressure, activity of daily living or adverse events (AEs, including supine 
hypertension). 
 Methodology: Only randomised, controlled trials (RCTs) were considered. 
Randomised, crossover trials were considered if outcomes were presented at the 
end of phase one (pre-crossover). 
Data sources and searches 
A search for published articles was performed using MEDLINE (1946 to June Week 3 2015), 
EMBASE (1974 to 2015 June 25), PubMed (no date limits) and the Cochrane Library 
(Cochrane Central Register of Controlled Trials, issue 5 of 12, May 2015). To reduce the risk 
of publication bias, conference proceedings and theses were searched using Web of Science 
(1970 to 2015) and ProQuest (1970-2015). In addition, reviewers searched the reference lists 
when reviewing full text articles, to identify additional studies. To identify ongoing and 
unpublished studies a search of The World Health Organisation International Clinical Trials 
Registry Platform was performed and Lundbeck, the pharmaceutical company which produced 
droxidopa, was contacted. All searches were performed on 26th June 2015.  A comprehensive 




All identified studies were collated into Endnote X7 where duplicates were removed. Titles 
and abstracts of the remaining studies were screened for eligibility by two reviewers (JF, JN); 
full text was reviewed where there was doubt about eligibility for inclusion. Following the 
screening process, full text was requested for all identified articles. 
Data extraction 
Data was extracted by two reviewers (JF, VS) onto forms derived from the Cochrane 
Collaboration (data extraction form version 3, April 2014) which were adapted for this topic 
review. Data included study design, methodology, duration and funding; participant numbers 
and characteristics; intervention and control dose, frequency and administration. Outcome 
measures recorded on scales were only considered for inclusion if they had been previously 
validated and described in peer-reviewed journals. Scales considered for this review were 
included in meta-analysis of continuous data if the unit of difference between points on the 
scale were consistent between points and there were at least 10 points on the scale. Where 
outcomes were reported at more than one time point, the final data point was extracted. Where 
possible, a change score was extracted for use in the quantitative analysis. Change in outcome 
from baseline to end of study are considered more efficient and powerful than final values, 
because it removes between-person variability from the analysis [19]. Where change values are 
not presented, the final values were included in the analysis because the difference in mean 
final values will on average be the same as the difference in mean change scores [19]. Where 
disagreement or inconsistency arose in data extraction, a third individual (JN) reviewed and 




Three reviewers (JF, VS, MPT) independently assessed the methodological quality of included 
trials using the criteria described in the Cochrane Handbook for Systematic Reviews of 
Interventions [19]. This included risk of bias assessment for selection, performance, detection, 
attrition, reporting and other identified bias. These were classed as high, low or uncertain. 
When disagreement arose, resolution occurred via arbitration (JN). To explore the possibility 
of publication bias we planned to construct funnel plots for all analyses of outcomes that 
contained more than 10 studies. 
Data synthesis and analysis 
The mean difference (MD) between groups was calculated for continuous outcome data 
(symptoms and blood pressure). For binary outcome data (adverse events and falls) the odds 
ratio (OR) and confidence interval (95% CI) was calculated. 
Forrest plots were visually inspected to identify obvious heterogeneity. Heterogeneity was 
quantified using the I2 statistic; an estimate of 0-40% was considered insignificant, 30-60% as 
moderate, 50-90% as substantial and 75-100% as considerable [19]. 
The fixed-effect model was used for all meta-analyses which were performed using Review 
Manager (version 5.3). As OH is very common and is associated with a variety of chronic 
diseases, a degree of clinical heterogeneity was expected. In the event of significant 
heterogeneity, a prospective subgroup analysis was planned in which two reviewers (JF, JN) 
would identify and remove studies involving OH due to distinctly different pathophysiology, 
in order to perform sensitivity analysis. If the exclusion of these trials had no effect on the 




Quality of evidence was judged independently for each outcome using the GRADE approach 
(The Grading of Recommendations Assessment, Development and Evaluation) by two 
reviewers (JF, MPT) [20]. A summary of findings table was created using GradePro software. 
Protocol and registration 
A protocol of the methodology used for this review was registered and published prospectively, 




The number of records identified, screened, excluded and selected are illustrated in Figure 1. 
Study characteristics 
Four studies meeting the inclusion criteria were identified, the characteristics of which can be 
seen in Table 1. Both studies by Hauser relate to the same trial but one presents data from an 
interim analysis [21] and the other presents the larger continued trial [22]. The participants in 
the interim analysis were not included in the subsequent larger trial. 
All included studies were reported in English, were double-blinded and randomised individual 
participants to droxidopa or placebo. Two of the completed studies were multinational [23 24], 
the remaining two studies were multicentre within the United States [21 22]. 
Two studies used an enriched-enrolment design, whereby participants who did not respond to 
droxidopa were screened out of the study before randomisation [23 24]. Three studies 
randomised participants to begin placebo or droxidopa, whereas one study randomised 
participants to continue with droxidopa or to withdraw to placebo [23]. Only one study stated 
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that analysis would be based on intention to treat [22]. Two studies were eight weeks long [21 
22], one was two weeks in duration[23] and one was completed after one week [24]. The mean 
dose of droxidopa administered across the four included studies (n 245) was 422.2 (±166·1) 
mg. 
Participant characteristics 
In the four pooled studies, 494 participants were randomised with a total of 420 (85%) 
remaining at completion. The commonest reasons for withdrawal were adverse events (n 19), 
lack of efficacy or treatment failure (n 18) or protocol violation (n 13). The mean age of 
participants was 66·5 (±13·2) years (range 18 to 92 years) and the reported mean baseline 
standing systolic BP was 93·7 (±18·2) mmHg across the four studies. All included participants 
had neurogenic OH (Parkinson’s disease 67%, pure autonomic failure 16%, multiple system 
atrophy 12%, non-diabetic autonomic neuropathy 3%, other 2·3%, dopamine beta-hydroxylase 
deficiency 0·2%). 
Risk of bias 
The risk of bias assessment for individual studies is summarised in Table 2. 
Effect of interventions 
All four studies used the Orthostatic Hypotension Questionnaire (OHQ) as an outcome 
measure. This validated, self-report questionnaire is divided into two parts, Symptom 
Assessment (composed of 6 items) and Daily Activity Score (4 items) [25]. Each item is scored 
from zero to 10 to quantify the severity of the symptom. 
Effect of droxidopa on symptoms 
All four studies used item one of the OHQ Symptom Assessment as an outcome measure to 
quantify the symptom of dizziness/light-headedness. Three out of the four studies reported the 
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change in dizziness score from baseline; for the remaining study the final values reported at 
the end of the study were included in analysis [24]. In the pooled analysis (4 RCTs, n 439) 
droxidopa was effective at reducing dizziness [-0·97 (95%CI -1·51, -0·42), p<0·001], with no 
statistical heterogeneity (I2 0%), see Figure 2. 
Three RCTs (n 394) reported the change in OH-related symptoms using a composite score for 
the six symptoms included in the OHQ Symptom Assessment (dizziness/light-headedness, 
vision disturbance, weakness, fatigue, trouble concentrating, head/neck discomfort) [22-24]. 
Pooled analysis demonstrated an improvement in symptoms when taking droxidopa (-0·52 
(95%CI -0·98, -0·06), p=0·03), with no statistical heterogeneity (I2 0%), see Figure 2. 
Effect of droxidopa on systolic BP 
All four RCTs (n 427) reported the change in standing systolic BP. Although the direction of 
treatment effect was inconsistent, a significant but small effect size was seen in the pooled 
analysis, with droxidopa increasing the standing systolic BP [3·9 (95%CI 0·1, 7·69), p=0·04]. 
There was minimal statistical heterogeneity (I2 10%), see Figure 2. 
Effect of droxidopa on activity of daily living 
Three RCTs (n 393) used part two of the OHQ as an outcome measure of daily activity [22-
24]. Change scores were reported for two studies [22 24] and end-point scores were reported 
in one [23]. Droxidopa was effective at reducing the impact of OH on daily activity in the 
pooled analysis [-0·86 (95%CI -1·34, -0·38), p<0·001], with no statistical heterogeneity (I2 
0%), see Figure 2. 
Adverse events 
The risk of AEs (serious, severe, withdrawal due to adverse event, headache, dizziness, fatigue, 
nausea and supine hypertension) are summarised in Supplementary Table 2. Event rates for all 
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AEs were similar between droxidopa and control groups. Pooled analysis included data for 
those who were randomised, excluding data which arose during dose titration. 
Falls were reported differently in the included studies. Two studies reported falls as an AE, 
reporting the number of participants who had fallen during the study [23 24]. Whereas two 
studies recorded falls as an outcome measure and reported the number of falls per person per 
week [21 22], however one of these studies also reported the number of people who had fallen 
[21]. Including the number of people who had fallen as an outcome measure in a pooled 
analysis, there was no reduction in risk of falling while taking droxidopa [n=314, OR 0·43 
(95%CI 0·18, 1·02), I2 28%], see Figure 2. 
All four studies reported absolute rates of supine hypertension. These were higher in the 
droxidopa (7·8%) group when compared to the controls (4·2%) but the relative risk was not 
significantly greater [4 RCTs, n 485, OR 1·93 (95% CI 0·87, 4·25), I2 0%], see Figure 2. Only 
one study reported the increase supine BP which was significantly greater in those randomised 
to droxidopa compared to placebo [7.6 (19.2) mm Hg, 0.8 (14.5) respectively, p <0.001] [24]. 
Risk of bias across studies 
As fewer than 10 studies were included in this review, a funnel plot of reporting bias was 
precluded [19]. 
Quality of evidence 
Table 3 summarises the quality and findings for each outcome measure, with a grading of 
the quality of evidence for the effects of droxidopa. 
Ongoing studies 
One study which completed in February 2015 has not yet reported the results [26]. This is an 
international, multicentre, randomised, double-blind, placebo-controlled trial of 12 weeks of 
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droxidopa therapy versus placebo in individuals with symptomatic OH secondary to primary 
autonomic failure. A further study, currently in progress, is performing a multicentre, 
randomised, double-blind, placebo-controlled trial of 12 week droxidopa therapy versus 
placebo in people with OH secondary to multiple system atrophy [27]. 
Discussion 
The results of this systematic review and meta-analysis support the use of droxidopa for the 
treatment of OH. Pooled analyses demonstrate that droxidopa is effective at reducing the 
symptom of dizziness, the overall symptom burden and the difficulty with activity. In addition, 
a beneficial effect on standing systolic BP was seen in those participants randomised to 
droxidopa. However, the direction of the effect on systolic BP was inconsistent across the four 
included studies. It is unclear why the effect on symptoms appears to be greater than the effect 
on systemic BP but there are several possible explanations. Firstly, the OHQ quantifies 
symptoms experienced over the previous week, in contrast to measures of BP which occur as 
discrete events, precluding a temporal relationship between symptoms and BP. It is also worth 
noting that orthostatic BP and symptoms are known to have a poor correlation and this is likely 
to be explained by varying degrees of cerebral autoregulation [28]. As well as peripheral 
actions, droxidopa also crosses the blood-brain-barrier, although its effect on cerebral 
autoregulation are unknown [29]. Given the more objective nature of BP in comparison to 
symptoms it would be wise to consider these outcomes together when considering the results 
of this meta-analysis. 
In the context of existing evidence for the treatment of OH, droxidopa looks promising for the 
future. Other commonly used agents such as midodrine and fludrocortisone do not have a 
robust evidence base and while many other agents have been studied few have generated 
sufficient benefits and have not translated into practice [6 8 9 30]. Although these results are 
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encouraging it must be noted that they reflect the short-term effects only. The data presented 
here are insufficient to consider the longer term clinical benefits of droxidopa therapy. 
All four studies used a three times per day schedule for the droxidopa, however only one study 
provides further details[23], including the rationale for this schedule and a 5pm limit on the 
final dose to avoid supine hypertension. A previous dose finding study found that droxidopa 
taken twice per day was effective at reducing symptoms without causing supine hypertension 
[16]. 
In the short-term there are no safety concerns regarding droxidopa. The rate of adverse events 
were similar between those randomised to droxidopa or placebo. Supine hypertension has been 
noted to occur more commonly in people taking existing therapies such as midodrine, but 
supine hypertension may also be a cardiovascular complication arising from autonomic failure 
[30 31]. The risk of supine hypertension was greater in those taking droxidopa in all four studies 
although pooled analysis did not demonstrate a significantly increased risk in comparison to 
placebo. Only one study reported the change in supine BP during intervention, which 
demonstrated only a modest increase in supine BP with droxidopa, albeit a significantly greater 
increase in comparison to those taking placebo [24]. 
Data concerning falls in those taking droxidopa is inconclusive. The reporting of falls data in 
the included studies was inconsistent, did not meet recommended methodologies for collecting 
and analysing falls data and follow-up was of insufficient length of time [32 33]. The true effect 
of droxidopa on falls therefore remains unknown. 
Conflict of interest between study authors and the drug manufacturer were present in all four 
included studies, with each study including employees of the pharmaceutical company as 
authors. Regardless of methodological quality, this introduces a significant risk of publication 
bias, limiting the overall quality of evidence. Furthermore, the enriched-enrolment design of 
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two studies was judged to introduce a high risk of selection/attrition bias [23 24]. By screening 
out non-responders before randomisation, studies are determining the effectiveness of an 
intervention in a cohort of people in whom the intervention is already effective. Although the 
enriched-enrolment design may increase the sensitivity of study results, which is useful in 
studies with high attrition rates, the effect size may be inflated and the results are less readily 
translated into clinical practice [34]. 
There was inconsistency in the timing of the primary endpoint which can be the result of an 
underlying reporting bias. This may have been present in one study in which the primary 
outcome measure and the timing of its measurement changed from week eight to week one 
[22]. There is no commonly agreed outcome data set for use in trials of OH. While individuals 
with OH may prioritise symptoms over BP measures, clinicians and academics may prefer the 
more objective nature of BP [35]. A core set of outcome measures may improve the quality of 
future clinical trials in OH. It has the potential to reduce reporting bias and improve data 
synthesis. An additional inconsistency was the reporting of concomitant therapies such as 
fludrocortisone and non-pharmacological therapies. Two studies mentioned salt and water 
intake, compression garments and sleeping with the head of the bed elevated, all of which 
feature in international recommendations but it is unclear how well participants adhered with 
these therapies [1 36]. However, it is possible that in the context of a clinical trial, participants 
are more likely to adhere with both the study intervention and other non-pharmacological 
therapies, which may explain the improvement seen in symptoms and BP in the placebo arm 
of some of the included studies. While the use of randomisation in the included studies should 
reduce the impact of concomitant therapy in the study outcomes, these are essential 
considerations which should be reported. 
Limitations of review 
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To reduce the risk of bias in study selection a range of data sources were searched, including 
conference proceedings, theses, clinical trials registries and contact with the drug manufacturer. 
However, the bibliographical databases did not include regional or country-specific databases 
(e.g. Latin America and the Caribbean LILACS database) which may have identified literature 
not published elsewhere. 
Although four RCTs is greater than the average number of studies in a pooled analysis, it was 
not possible to make a quantitative analysis of publication bias [37]. It is probable that there is 
a degree of publication bias given the involvement of the pharmaceutical company (Lundbeck) 
in all of the included studies. However, it is worth noting that Lundbeck (manufacturer of 
droxidopa) register all of their clinical trials protocols prospectively on a clinical trials register, 
which goes some way to reduce the impact of publication bias. 
Studies measuring the longer-term efficacy, effectiveness and adverse effects of droxidopa are 
required. Ideally, to reduce the risk of bias these studies should avoid an enriched-enrolment 
design and be conducted independently of pharmaceutical companies. 
The exclusion of non-randomised clinical trials may have missed important relevant studies, 
which in the context of rare diseases (such as dopamine-β hydroxylase deficiency, DBHD) may 
be clinically important. Indeed, in the pooled sample of 494 participants only one had DBHD. 
A more inclusive, broader review may be more informative for such rare diseases. 
Conclusions 
There is moderate level of evidence that droxidopa improves both dizziness and general OH-
related symptoms in people with neurogenic OH, in the short-term. There is also moderate 
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Figure 1. Study selection process 
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Interventions  Participants’  use  of  non‐pharmacological  therapy  was  not  monitored.  Other 
vasoconstricting medication was not permitted; fludrocortisone was continued in 
30  participants  in  the  droxidopa  arm  and  16  in  the  placebo  arm.  The  study 
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were  not  monitored.  Other  vasoconstricting  agents  were  not  permitted. 














  Selection bias  Performance bias  Attrition bias  Reporting bias  Other bias 






Biaggioni 2015  Unclear *  Unclear †  Unclear ǂ  Low  High § Unclear ǁ  High ¶ 
Hauser 2014  Unclear *  Unclear †  Low  Low  Low  Low  High ¶ 
Hauser 2015  Unclear *  Unclear †  Low  Low  Low  Low  High ¶ 







































































Supplementary Table 1. Comprehensive list of search terms used in systematic review 
Database Search strategy 
MEDLINE 
1946 to June Week 
3 2015 
 
1. randomized controlled trial.pt. 
2. controlled clinical trial.pt. 
3. randomized.ab. 
4. placebo.ab. 




9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 
10. exp animals/ not humans.sh. 
11. 9 not 10 
12. hypotension, orthostatic.sh. 
13. orthostatic intolerance.sh. 
14. postural hypotension.mp. 







22. 16 or 17 or 18 or 19 or 20 or 21 
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23. 11 and 15 and 22 
EMBASE 




2 clinical trial.mp. 
3 exp health care quality 
4 1 or 2 or 3 
5 orthostatic hypotension.sh. 
6 postural hypotension.mp. 
7 orthostatic intolerance.sh. 
8 orthostatic stress.sh. 
9 standing.sh. 








18 11 or 12 or 13 or 14 or 15 or 16 or 17 




#1. randomized controlled trial [pt] 
#2. controlled clinical trial [pt] 
#3. randomized [tiab] 
#4. placebo [tiab] 
#5. drug therapy [sh] 
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#6. randomly [tiab] 
#7. trial [tiab] 
#8. groups [tiab] 
#9. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 
#10. animals [mh] NOT humans [mh] 
#11. #9 NOT #10 
#12. hypotension, orthostatic [mesh] 
#13. orthostatic intolerance [mesh] 
#14. #12 OR #13 
#15. droxidopa [mesh] 






issue 6 of 12, May 
2015 
 
#1. orthostatic hypotension 
#2. MeSH descriptor: [hypotension, orthostatic] explode all trees
#3. orthostatic intolerance 
#4. MeSH descriptor: [orthostatic intolerance] explode all trees 
#5. #1 or #2 or #3 or #4 
#6. droxidopa 
#7. MeSH descriptor: [Droxidopa] explode all trees 
#8. #6 or #7 
#9. #5 and #8 
Web Of Science 
1970 to 2015 
 
#1. TS=(orthostatic hypotension) 
#2. TS=(orthostatic intolerance) 
#3. TS=(postural hypotension) 





#7. TS=(clinical trial) 
#8. TS=(placebo) 
#9. #6 OR #7 OR #8 




(MESH(hypotension, orthostatic) OR MESH(orthostatic 
intolerance) OR MESH(Posture) OR 
AB,TI,DISKW,FT(orthostatic)) AND (MESH(Droxidopa) OR 
MESH(Droxidopa, (DL-Tyr) -Isomer) OR 
AB,TI,DISKW,FT(Droxidopa)) AND YR(1970-2015) AND 
(MESH(Treatment Outcome) OR MESH(Clinical Trial) OR 
TI,AB,DISKW,FT(random*)) 








Appendix Table 2. Adverse events (AEs) 
 
Droxidopa Placebo Risk (odds ratio with 
95% CI) 
Severe AE 8/245 11/240 0·66 (0·26, 1·68) 
Biaggioni 0/51 2/50 
Kaufmann 0/81 0/81 
Hauser 2015 8/89 9/82 
Hauser 2014 0/24 0/27 
Serious AE 5/245 5/240 0·93 (0·28, 3·12) 
Biaggioni 0/51 1/50 
Kaufmann 0/81 0/81 
Hauser 2015 5/89 4/82 
Hauser 2014 0/24 0/27 
Discontinued due to AE 11/221 7/213 1·47 (0·57, 3·82) 
Biaggioni 0/51 2/50 
Kaufmann 0/81 0/81 
Hauser 2015 11/89 5/82 
Hauser 2014 not reported not reported 
Headache 23/245 12/240 1·91 (0·94, 3·92) 
Biagionni 2/51 4/50 
Kaufmann 6/81 0/81 
Hauser 2015 12/89 6/82 
Hauser 2014 3/24 2/27 
Dizziness 16/245 7/240 2·32 (0·93, 5·77) 
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Biagionni 2/51 1/50 
Kaufmann 3/81 1/81 
Hauser 2015 9/89 4/82 
Hauser 2014 2/24 1/27 
Fatigue 9/221 8/213 1·06 (0·41, 2·74) 
Biagionni 0/51 1/50 
Kaufmann 2/81 2/81 
Hauser 2015 7/89 5/82 
Hauser 2014 not reported not reported 
Nausea 12/245 7/240 1·67 (0·67, 4·16) 
Biagionni 0/51 2/50 
Kaufmann 2/81 0/81 
Hauser 2015 7/89 2/82 
Hauser 2014 3/24 3/27 
Supine hypertension 19/245 10/240 1·93 (0·87 to 4·25) 
Biagionni (not defined) 7/51 3/50 
Kaufmann (systolic BP 
>180) 
4/81 2/81 
Hauser 2015 (systolic BP 
>180) 
7/89 4/82 
Hauser 2014 (systolic BP 
>180) 
1/24 1/27 
 
 
 
